Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Stem cell therapy hope for kidney transplant patients

10 October 2011

By George Frodsham

Appeared in BioNews 628

Scientists have found a new method of suppressing the automatic rejection of donated kidneys in transplant patients, by using the donor's stem cells. In a small trial carried out at Stanford University, California, eight out of 12 patients were able to stop taking anti-rejection drugs, which are usually a lifelong necessity, following this treatment.

Soon after their transplants, each of the patients in the study underwent a procedure where their lymph nodes, spleen and thymus were given a dose of radiation to kill some of their immune system's white blood cells. This was in addition to the patient taking the standard course of two anti-rejection drugs.

About ten days after the radiation treatment, the patient was injected with stem cells from the donor's blood. They then differentiate into white blood cells and become part of the recipient's immune system, and will not attack the new kidney. If the stem cells mix favourably with the patient's own cells, the patient can be taken off the first anti-rejection drug after a month, and the second after six months.

'Those eight that we've taken off the drugs, they've had no rejection, no evidence of the kidney being damaged', said Dr Samuel Strober, the immunologist who is leading the study, which was published in the New England Journal of Medicine.

All of the eight patients treated successfully have now been off the immunosuppressant drugs completely for over a year, including one for over three years. Dr Strober, explained the other four have 'failed to meet our strict drug withdrawal criteria', but have suffered no side effects from the treatment.

Currently, all transplant patients need the drug course to prevent their body from rejecting the donor organ. This is the case even if the donor is a perfect match in terms of surface markers – called HLA (human leukocyte antigen) antigen – which reduces the risk of the donated kidney being rejected. However, they can pose problems in the long-term.

'While they help ward off rejection of the new organ by the patient's own immune system, these drugs carry their own risk of side effects, such as high blood pressure, diabetes and cancer', said Dr Strober.

All the patients in this on-going clinical trial are perfect matches with their donors, but the work is now being expanded to include patients with mismatched donors, where only 50 percent of their HLA antigens match the patient's.

'Our preclinical lab results show that we can use mismatched recipients as well as matched, and that gives us confidence to move ahead', added Dr Strober.

However, Dr Flavio Vincenti, a kidney transplant expert at the University of California, San Francisco, cautioned against over-optimism. He said it was not known whether the delicate balance of the immune system can be maintained in the long-term. 'I would caution patients and physicians that this gives us maybe an idea on a mechanism of action, but from a practical point of view, it will have very limited application', Dr Vincenti told the San Francisco Chronicle.

SOURCES & REFERENCES
Induced Immune Tolerance for Kidney Transplantation
New England Journal of Medicine | 06 October 2011
 
New Scientist | 05 October 2011
 
Eurekalert | 05 October 2011
 
San Francisco Chronicle | 05 October 2011
 
US News: Health | 06 October 2011
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

26 August 2014 - by Dr James Heather 
Researchers from the MRC Centre for Regenerative Medicine in Edinburgh, UK, have for the first time produced complete working organs from genetically 'reprogrammed' cells. Engineered cells were inserted into adult mice, where they grew into what appeared to be functional thymuses....
21 May 2012 - by Victoria Kay 
The world's first stem cell drug has been approved by Canadian authorities. US biotech company, Osiris Therapeutics, has been given the go-ahead to market its drug, Prochymal, for the treatment of graft-versus-host-disease (GvHD) in children who fail to respond to steroids....
12 March 2012 - by Dr Rebecca Robey 
Stem cell therapy may remove the need for organ transplant recipients to have lifelong drug treatment to combat the risk of rejection, which would dramatically improve patients' quality of life...
14 November 2011 - by Rosemary Paxman 
A new technique to transform skin cells into immune cells has been used in the laboratory to hunt for and attack cancer, report scientists after a proof-of-principle study...

27 June 2011 - by Dr Rebecca Robey 
Scientists in Japan have reported the production of mice that have rat's organs. They suggest that one day this technique could be used to grow spare human organs in another species such as pigs, easing organ shortages and reducing long waiting times for transplants...
18 April 2011 - by Dr Rosie Gilchrist 
Scientists at Edinburgh University have grown kidney structures in the laboratory in a step they hope will lead to organs being grown for transplant patients from their own stem cells...
10 November 2008 - by Dr Charlotte Maden 
New organs from 'designer pigs' could be ready to use in humans within a decade. The hope is to transplant the organs into humans who require them to help solve the problem of the shortage of transplant organs. Lord Robert Winston, the fertility expert from Imperial College...
02 May 2006 - by BioNews 
A team of US scientists has managed to successfully treat mice with symptoms of a genetic kidney disease, using bone marrow stem cells. The researchers, based at the Beth Israel Deaconess Medical Center, transplanted stem cells into animals affected by Alport syndrome, and saw a significant improvement in their condition...
30 July 2001 - by BioNews 
Collaborative research between scientists from the UK Imperial Cancer Research Fund and the Imperial College School of Medicine, London, has shown for the first time that bone marrow cells are able to turn into kidney cells. The researchers believe that this discovery will help pave the way to treating kidney...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation